The Effects of Low Intensity Endurance Exercise on Improving Mitochondrial Function, Cell Bioelectrical Impedance Phase Angle, Fatigue and Quality of Life in Lung Cancer Patients With Cancer-related Fatigue
4 settembre 2026 aggiornato da: Taipei Medical University
To conduct a randomized controlled trial (RCT) targeting lung cancer patients with cancer-related fatigue to achieve the following objectives:
Objective 1: To investigate whether a low-intensity endurance exercise intervention can effectively improve mitochondrial DNA content, mitochondrial function, mitochondrial oxidative phosphorylation complex enzyme concentrations, cellular bioelectrical impedance phase angle, cancer-related fatigue, and quality of life in lung cancer patients with cancer-related fatigue.
Objective 2: To explore whether the low-intensity endurance exercise intervention improves cancer-related fatigue and quality of life in lung cancer patients through direct or indirect effects by modulating mitochondrial DNA content, mitochondrial function, mitochondrial oxidative phosphorylation complex enzyme concentrations, and cellular bioelectrical impedance phase angle.
Panoramica dello studio
Stato
Reclutamento
Condizioni
Descrizione dettagliata
After enrollment, subjects will be randomly assigned to three groups:
- Control Group: No exercise intervention will be implemented. Subjects will maintain their usual lifestyle and daily activities.
- Low-Intensity Endurance Continuous Training Group (Level 2 low-intensity continuous endurance exercise): Subjects will perform Level 2 low-intensity endurance exercise training for at least 30 continuous minutes per day, at least 5 days per week (75-80% peak heart rate [HR peak], Rating of Perceived Exertion [RPE] 11-12; the exerciser perceives the exertion as light, but breathing sounds increase, and they can comfortably hold a conversation during exercise but need to pause occasionally for breath). This continuous low-intensity endurance training will last for 12 consecutive weeks. Each exercise session will begin with a 5-minute warm-up, followed by 30 minutes of continuous low-intensity endurance exercise, and conclude with a gradual 10-minute cool-down until completely stopping.
- Low-Intensity Endurance Interval Training Group (Alternating 3 minutes of Level 2 low-intensity endurance exercise and 3 minutes of Level 1 lowest-intensity endurance exercise, for a total of 5 alternating cycles): Subjects will perform alternating Level 2 and Level 1 (65-75% HR peak, RPE <11; the exerciser perceives the exertion as very light) exercise training for at least 30 continuous minutes per day, at least 5 days per week. This low-intensity endurance interval training will last for 12 consecutive weeks. Each exercise session will begin with a 5-minute warm-up, followed by 30 minutes of low-intensity endurance interval training, and conclude with a gradual 10-minute cool-down until completely stopping.
Tipo di studio
Interventistico
Iscrizione (Stimato)
150
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Hsiu Ting Tsai, PhD
- Numero di telefono: 6330 886227361661
- Email: hsiuting@tmu.edu.tw
Backup dei contatti dello studio
- Nome: Hsin-Hui Huang, Master's degree
- Numero di telefono: 6330 886227361661
- Email: d432113014@tmu.edu.tw
Luoghi di studio
-
-
-
Taipei, Taiwan
- Reclutamento
- Taipei Medical University
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Patients who are diagnosed with lung cancer by a physician ;
- Patients aged 20-70 years;
- Patients who are determined by a physician, after assessment of their physical condition, to be suitable for exercise;
- Patients who have graduated from elementary school or above.
Exclusion Criteria:
- Patients who are unable to communicate in Mandarin, Taiwanese, or Hakka;
- Patients who are determined by a physician to be physically unsuitable for performing any exercise.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Control Group
No exercise intervention will be implemented, and participants will carry out their daily activities according to their previous lifestyle habits.
|
|
|
Sperimentale: Continuous Training Group
Level 2 low-intensity continuous endurance exercise: Participants will perform Level 2 low-intensity endurance exercise training continuously for at least 30 minutes per day, at least 5 days per week, for 12 consecutive weeks.
The exercise intensity will be 75-80% of peak heart rate, with a rating of perceived exertion of 11-12.
At this intensity, participants will perceive the exercise as easy, but their breathing sound will increase; they will be able to converse comfortably during exercise but may occasionally need to pause for breath
|
Participants perform continuous low-intensity endurance exercise for 30 minutes per day, 5 days per week, for 12 weeks at 75%-80% peak heart rate and RPE 11-12.
|
|
Sperimentale: Intermittent Training Group
Participants will perform alternating training consisting of 3 minutes of Level 2 low-intensity endurance exercise and 3 minutes of Level 1 minimal-intensity endurance exercise, for a total of 5 alternating cycles.
The training will be performed continuously for at least 30 minutes per day, at least 5 days per week, for 12 consecutive weeks.
Level 1 exercise intensity will be 65-75% of peak heart rate, with a rating of perceived exertion below 11, indicating that participants perceive the exercise as very easy.
|
Participants perform alternating low-intensity endurance training consisting of 3-minute Level 2 exercise and 3-minute Level 1 exercise for 30 minutes per day, 5 days per week, for 12 weeks.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in Cancer-Related Fatigue (CRF)
Lasso di tempo: Baseline, Week 6, and Week 12
|
Evaluated by the Brief Fatigue Inventory-Taiwan (BFI-T).
The total score ranges from 0 to 90, with higher scores indicating greater fatigue severity and interference with daily life.
Higher scores indicate greater fatigue severity.
|
Baseline, Week 6, and Week 12
|
|
Change from baseline in mitochondrial oxidative phosphorylation complex enzyme concentrations
Lasso di tempo: Baseline, Week 6, and Week 12
|
Concentrations of mitochondrial complex enzymes (Complex I-V) determined via ELISA at an absorbance wavelength of 600 nm.
Expressed in ng/mL
|
Baseline, Week 6, and Week 12
|
|
Change from baseline in Quality of Life (QoL)
Lasso di tempo: Baseline, Week 6, and Week 12
|
Evaluated using the Functional Assessment of Cancer Therapy-General; FACT-G.
The scale comprises four subscales: (1) Physical Well-Being (PWB): 7 items, score range 0-28; (2) Social/Family Well-Being (SWB): 7 items, score range 0-28; (3) Emotional Well-Being (EWB): 6 items, score range 0-24; and (4) Functional Well-Being (FWB): 7 items, score range 0-28.
Higher scores indicate better quality of life
|
Baseline, Week 6, and Week 12
|
|
Change from baseline in phase angle and skeletal muscle mass
Lasso di tempo: Baseline, Week 6, and Week 12
|
Measured using the InBody S10 bioelectrical impedance analyzer.
Phase angle is expressed in degrees (°), and skeletal muscle mass is expressed in kilograms (kg).
|
Baseline, Week 6, and Week 12
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
10 marzo 2025
Completamento primario (Stimato)
31 luglio 2027
Completamento dello studio (Stimato)
31 luglio 2027
Date di iscrizione allo studio
Primo inviato
26 agosto 2026
Primo inviato che soddisfa i criteri di controllo qualità
4 settembre 2026
Primo Inserito (Effettivo)
8 settembre 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
8 settembre 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
4 settembre 2026
Ultimo verificato
1 agosto 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- N202404024
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .